TEL AVIV, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the entry into a framework agreement for mutual termination of merger, dated October 6, 2025, by and between the Company, AutoMax Motors Ltd. ("AutoMax") and SciSparc Merger Sub Ltd. This agreement outlines key steps to resolve prior commitmen ...

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]

Group 1 - SciSparc Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days [1][2] - The compliance determination by Nasdaq indicates that the prior bid price deficiency matter is now closed [2] - SciSparc is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [3] Group 2 - The company is led by an experienced team of senior executives and scientists, emphasizing its expertise in cannabinoid pharmaceuticals [3] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [3]

Core Viewpoint - SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA), which may provide enhanced pain and fever relief with lower doses and fewer side effects compared to traditional paracetamol use [1][2]. Group 1: Patent and Innovation - The newly published patent introduces a combination of paracetamol and PEA that could lead to safer and more effective treatment options for millions globally [2]. - The combination aims to reduce the required dosage of paracetamol, thereby minimizing risks such as liver damage while improving outcomes for various types of pain and fever [3]. Group 2: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4]. - The company is currently engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4].